Post by
curiousj on Jun 10, 2021 12:05pm
Re: Exelon acquisition
considering the price paid for Exelon, do you think given the news from Biogen, that Knight paying 3.8x sales for the product was too much? Especially knowing that Novartis can still compete with Knight through Sandoz
Comment by
MrMugsy on Jun 10, 2021 12:14pm
And ... Demand may grow up to 10x by 2050 And ... The potential to enter smaller geographies is certainly a GUD focus And ... GUD promotion will have a positive effect on sales growth Oh ... and ... future partnerships with Novartis are likely - new Exelon sales in ROW geographies may seal a bigger deal for other Novartis drugs.
Comment by
Chianchin on Jun 11, 2021 7:54am
Biogen (BIIB) – Biogen added 1.4% in the premarket after UBS upgraded the drug maker’s stock to “buy” from “neutral,” and Bernstein raised its rating to “outperform” from “market perform.” Both firms base their upgrades on the potential sales bump from the Food and Drug Administration’s approval this week of Alzheimer’s disease treatment Aduhelm.
Comment by
Spirou25 on Jun 11, 2021 8:14am
You are pathetic. Two options : 1) You're paid to post here. 2) You need to take medication.
Comment by
Chianchin on Jun 11, 2021 1:20pm
Patetic? Simply reprting the Bermstein Firm upgrade of Biogem. It is a simple a zero sum game/business situation where losses of business incurred by a company/player in transactions/sales result in an equal increase in gains/sales of the opposing company player. Simple math
Comment by
schocor on Jun 11, 2021 1:26pm
Are you expecting latin America to approved Biogem? Seriously? What is your timeline for this approval look like? I am expecting "crickets".
Comment by
Spirou25 on Jun 11, 2021 2:02pm
The two drugs don't even compete
Comment by
Chianchin on Jun 11, 2021 3:01pm
Most midle class Latam resident travel to South Florida. The first spoken laguage there is espagnol and half of the condos are owned by person living in Latam. They also got vaccinated way before we did in Canada. They care about their seniors a lot in Latam. Try to read Latam news and save yourself some more $$ losses